KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Cash & Equivalents (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Cash & Equivalents for 16 consecutive years, with $33.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 65.36% to $33.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.0 million, a 65.36% decrease, with the full-year FY2025 number at $33.0 million, down 65.36% from a year prior.
  • Cash & Equivalents was $33.0 million for Q4 2025 at Biolife Solutions, up from $29.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $95.4 million in Q4 2024 to a low of $19.1 million in Q1 2023.
  • A 5-year average of $43.0 million and a median of $29.6 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 1290.81% in 2021, then plummeted 72.17% in 2022.
  • Biolife Solutions' Cash & Equivalents stood at $69.9 million in 2021, then tumbled by 72.17% to $19.4 million in 2022, then skyrocketed by 43.48% to $27.9 million in 2023, then soared by 241.93% to $95.4 million in 2024, then plummeted by 65.36% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Cash & Equivalents are $33.0 million (Q4 2025), $29.5 million (Q3 2025), and $31.9 million (Q2 2025).